Calidi Biotherapeutics Shows Promising Preclinical Data for Cancer Therapies
Event summary
- Calidi Biotherapeutics presented new preclinical data on July 23, 2026 at the AACR D3 Conference in Boston.
- Data highlights advances in CLD-401 program and a novel TCE targeting the EpCam receptor.
- CLD-401 is expected to enter clinical trials in Q1 2027.
- RedTail platform demonstrated ability to deliver genetic medicines to distal tumor sites.
The big picture
Calidi's presentation comes as biotech companies increasingly focus on systemic delivery of genetic medicines for metastatic cancers. The RedTail platform's ability to shield viruses from immune clearance represents a potential advantage in reaching difficult-to-treat tumor sites. Success in translating these preclinical results into clinical outcomes could position Calidi as a key player in targeted cancer therapies.
What we're watching
- Clinical Timelines
- Whether Calidi can maintain its Q1 2027 timeline for CLD-401 clinical trials.
- Platform Efficacy
- How the RedTail platform's ability to target distal tumor sites will translate into clinical efficacy.
- Competitive Positioning
- The pace at which Calidi can differentiate itself in the crowded cancer immunotherapy space.
Related topics